Jingjing Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jingjing Lin has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Ailin Qi
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China
1 shared publication- Beilei Hu
Department of Neurology of the Second Affiliated Hospital and Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, China
1 shared publication - Bingting Pan
Department of Neonatology, The Second Affiliated Hospital, Yuying Children’s Hospital of Wenzhou Medical University, Zhejiang, China
1 shared publication - Congcong Xu
Department of Neonatology, The Second Affiliated Hospital, Yuying Children’s Hospital of Wenzhou Medical University, Zhejiang, People’s Republic of China
1 shared publication Di Xu
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China
1 shared publicationHong Jiang
The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China
1 shared publication
Latest Publications
- Open Access
- 8 February 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 968, 176406
Catalpol alleviates hypoxia ischemia-induced brain damage by inhibiting ferroptosis through the PI3K/NRF2/system Xc-/GPX4 axis in neonatal rats
- 8 February 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 968, 176406
Open AccessCatalpol alleviates hypoxia ischemia-induced brain damage by inhibiting ferroptosis through the PI3K/NRF2/system Xc-/GPX4 axis in neonatal rats
- Open Access
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 8336070
Simvastatin Inhibits NLRP3 Inflammasome Activation and Ameliorates Lung Injury in Hyperoxia‐Induced Bronchopulmonary Dysplasia via the KLF2‐Mediated Mechanism
Bronchopulmonary dysplasia (BPD) is a chronic lung disease commonly found in premature infants. Excessive inflammation and oxidative stress contribute to BPD occurrence and development. Simvastatin, as an inhibitor of HMG‐CoA reductase, has been reported to have antioxidative and anti‐inflammatory effects. However, its effect and possible mechanisms in hyperoxia‐induced lung injury are rarely reported. In this study, in vivo and in vitro experiments were conducted to investigate whether simvastatin could ameliorate hyperoxia‐induced lung injury and explore its potential mechanism. For the in vivo study, simvastatin could improve alveolar development after hyperoxic lung injury and reduce hyperoxic stress and inflammation. The in vitro study revealed that simvastatin can reduce inflammation in A549 cells after high‐oxygen exposure. Simvastatin suppressed NLRP3 inflammasome activation and played anti‐inflammatory and antioxidant roles by increasing KLF2 (Krüppel‐like factor 2) expression. In vitro experiments also revealed that these effects of simvastatin were partially reversed by KLF2 shRNA, indicating that KLF2 was involved in simvastatin effects. In summary, our findings indicate that simvastatin could downregulate NLRP3 inflammasome activation and attenuate lung injury in hyperoxia‐induced bronchopulmonary dysplasia via KLF2‐mediated mechanism.
- 1 January 2022
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2022 (1) , 8336070
Open AccessSimvastatin Inhibits NLRP3 Inflammasome Activation and Ameliorates Lung Injury in Hyperoxia‐Induced Bronchopulmonary Dysplasia via the KLF2‐Mediated Mechanism
Bronchopulmonary dysplasia (BPD) is a chronic lung disease commonly found in premature infants. Excessive inflammation and oxidative stress contribute to BPD occurrence and development. Simvastatin, as an inhibitor of HMG‐CoA reductase, has been reported to have antioxidative and anti‐inflammatory effects. However, its effect and possible mechanisms in hyperoxia‐induced lung injury are rarely reported. In this study, in vivo and in vitro experiments were conducted to investigate whether simvastatin could ameliorate hyperoxia‐induced lung injury and explore its potential mechanism. For the in vivo study, simvastatin could improve alveolar development after hyperoxic lung injury and reduce hyperoxic stress and inflammation. The in vitro study revealed that simvastatin can reduce inflammation in A549 cells after high‐oxygen exposure. Simvastatin suppressed NLRP3 inflammasome activation and played anti‐inflammatory and antioxidant roles by increasing KLF2 (Krüppel‐like factor 2) expression. In vitro experiments also revealed that these effects of simvastatin were partially reversed by KLF2 shRNA, indicating that KLF2 was involved in simvastatin effects. In summary, our findings indicate that simvastatin could downregulate NLRP3 inflammasome activation and attenuate lung injury in hyperoxia‐induced bronchopulmonary dysplasia via KLF2‐mediated mechanism.